{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:02:45Z","timestamp":1766181765989,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jsat.2021.108656","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T21:19:12Z","timestamp":1636406352000},"page":"108656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up"],"prefix":"10.1016","volume":"135","author":[{"given":"Zhanna","family":"Gaulen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u016brat\u0117","family":"\u0160altyt\u0117 Benth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Thore","family":"Fadnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida Halvorsen","family":"Brenna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Tanum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2017","series-title":"Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003-2015 (update) the CBHSQ report","author":"Alderks","key":"10.1016\/j.jsat.2021.108656_bb0005"},{"year":"2011","series-title":"Public policy statement: definition of addiction","key":"10.1016\/j.jsat.2021.108656_bb0010"},{"key":"10.1016\/j.jsat.2021.108656_bb0015","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.addbeh.2018.11.008","article-title":"Relapse after inpatient substance use treatment: A prospective cohort study among users of illicit substances","volume":"90","author":"Andersson","year":"2019","journal-title":"Addictive Behaviors"},{"issue":"1","key":"10.1016\/j.jsat.2021.108656_bb0020","doi-asserted-by":"crossref","first-page":"1565624","DOI":"10.1080\/23311908.2019.1565624","article-title":"Predictors of quality of life of patients in opioid maintenance treatment in the first year in treatment","volume":"6","author":"Carlsen","year":"2019","journal-title":"Cogent Psychology"},{"key":"10.1016\/j.jsat.2021.108656_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/SAR.S221618","article-title":"Opioid and polydrug use among patients in opioid maintenance treatment","volume":"11","author":"Carlsen","year":"2020","journal-title":"Substance Abuse and Rehabilitation"},{"key":"10.1016\/j.jsat.2021.108656_bb0030","series-title":"Happy people live longer: Subjective well-being contributes to health and longevity","first-page":"1","volume":"3(1)","author":"Diener","year":"2011"},{"issue":"1","key":"10.1016\/j.jsat.2021.108656_bb0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1207\/s15327752jpa4901_13","article-title":"The satisfaction with life scale","volume":"49","author":"Diener","year":"1985","journal-title":"Journal of Personality Assessment"},{"key":"10.1016\/j.jsat.2021.108656_bb0040","doi-asserted-by":"crossref","DOI":"10.1186\/s13011-015-0031-4","article-title":"Opioid dependency rehabilitation with the opioid maintenance treatment programme - A qualitative study from the clients' perspective","volume":"10","author":"Granerud","year":"2015","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"10.1016\/j.jsat.2021.108656_bb0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jsat.2017.01.016","article-title":"One-year sobriety improves satisfaction with life, executive functions and psychological distress among patients with polysubstance use disorder","volume":"76","author":"Hagen","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1016\/j.jsat.2021.108656_bb0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1037\/1064-1297.15.2.134","article-title":"Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment","volume":"15","author":"Hyman","year":"2007","journal-title":"Experimental and Clinical Psychopharmacology"},{"issue":"4","key":"10.1016\/j.jsat.2021.108656_bb0055","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1037\/a0017324","article-title":"A stress-coping profile of opioid dependent individuals entering naltrexone treatment: A comparison with healthy controls","volume":"23","author":"Hyman","year":"2009","journal-title":"Psychology of Addictive Behaviors"},{"issue":"5","key":"10.1016\/j.jsat.2021.108656_bb0060","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/scan\/nsz026","article-title":"Naltrexone alters responses to social and physical warmth: Implications for social bonding","volume":"14","author":"Inagaki","year":"2019","journal-title":"Social Cognitive and Affective Neuroscience"},{"issue":"7","key":"10.1016\/j.jsat.2021.108656_bb0065","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: A systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.jsat.2021.108656_bb0070","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1176\/appi.ajp.158.3.433","article-title":"Life satisfaction and suicide: A 20-year follow-up study","volume":"158","author":"Koivumaa-Honkanen","year":"2001","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.jsat.2021.108656_bb0075","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000259089","article-title":"EUROPASI: European adaptation of a multidimensional assessment instrument for drug and alcohol dependence","volume":"1","author":"Kokkevi","year":"1995","journal-title":"European Addiction Research"},{"issue":"1","key":"10.1016\/j.jsat.2021.108656_bb0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-244X-7-37","article-title":"Five-factor model personality traits in opioid dependence","volume":"7","author":"Korn\u00f8r","year":"2007","journal-title":"BMC Psychiatry"},{"issue":"5","key":"10.1016\/j.jsat.2021.108656_bb0085","first-page":"533","article-title":"A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo,Norway","volume":"97","author":"Krook","year":"2002"},{"issue":"6","key":"10.1016\/j.jsat.2021.108656_bb0090","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1192\/bjp.bp.108.055319","article-title":"Naltrexone implants after in-patient treatment for opioid dependence: Randomised controlled trial","volume":"194","author":"Kunoe","year":"2009","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2021.108656_bb0095","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40360-016-0061-1","article-title":"Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)","volume":"17","author":"Kunoe","year":"2016","journal-title":"BMC Pharmacology and Toxicology"},{"issue":"2","key":"10.1016\/j.jsat.2021.108656_bb0100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jamapsychiatry.2018.3537","article-title":"Anxiety, depression, and insomnia among adults with opioid dependence treated with extended-release naltrexone vs buprenorphine-naloxone: A randomized clinical trial and follow-up study","volume":"76","author":"Latif","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2021.108656_bb0105","first-page":"44","article-title":"The case for considering quality of life in addiction research and clinical practice","volume":"6","author":"Laudet","year":"2011","journal-title":"Addiction Science & Clinical Practice"},{"issue":"2","key":"10.1016\/j.jsat.2021.108656_bb0110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/10826080802714462","article-title":"Don't wanna go through that madness no more: Quality of life satisfaction as predictor of sustained remission from illicit drug misuse","volume":"44","author":"Laudet","year":"2009","journal-title":"Substance Use & Misuse"},{"issue":"10118","key":"10.1016\/j.jsat.2021.108656_bb0115","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jsat.2021.108656_bb0120","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1747-597X-3-2","article-title":"Satisfaction with life and opioid dependence","volume":"3","author":"Luty","year":"2008","journal-title":"Substance Abuse Treatment, Prevention, and Policy"},{"key":"10.1016\/j.jsat.2021.108656_bb0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jsat.2019.01.019","article-title":"Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support","volume":"100","author":"Muthulingam","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"year":"2005","author":"Nagin","key":"10.1016\/j.jsat.2021.108656_bb0130"},{"issue":"17","key":"10.1016\/j.jsat.2021.108656_bb0135","first-page":"1567","article-title":"Suicide: A silent contributor to opioid-overdose","volume":"378","author":"Oquendo","year":"2018"},{"issue":"2","key":"10.1016\/j.jsat.2021.108656_bb0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/17439760701756946","article-title":"The satisfaction with life scale and the emerging construct of life satisfaction","volume":"3","author":"Pavot","year":"2008","journal-title":"The Journal of Positive Psychology"},{"key":"10.1016\/j.jsat.2021.108656_bb0145","series-title":"Review of the Satisfaction With Life Scale Assessing well-being: The collected works of Ed Diener","first-page":"101","author":"Pavot","year":"2009"},{"issue":"2","key":"10.1016\/j.jsat.2021.108656_bb0150","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1207\/s15327752jpa7002_11","article-title":"The temporal satisfaction with life scale","volume":"70","author":"Pavot","year":"1998","journal-title":"Journal of Personality Assessment"},{"issue":"3","key":"10.1016\/j.jsat.2021.108656_bb0155","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jsat.2013.10.006","article-title":"From methadone to buprenorphine: Changes during a 10year period within a national opioid maintenance treatment programme","volume":"46","author":"Riksheim","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.jsat.2021.108656_bb0160","doi-asserted-by":"crossref","first-page":"12298","DOI":"10.1038\/s41598-018-29881-x","article-title":"Genetics, personality and wellbeing. A twin study of traits, facets and life satisfaction","volume":"8","author":"R\u00f8ysamb","year":"2018","journal-title":"Scientific Reports"},{"issue":"6","key":"10.1016\/j.jsat.2021.108656_bb0165","first-page":"303","article-title":"Availability of extended-release naltrexone may increase the number of opioid-dependent individuals in treatment: Extension of a randomized clinical trial","volume":"25","author":"Solli","year":"2019"},{"issue":"10","key":"10.1016\/j.jsat.2021.108656_bb0170","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1111\/add.14278","article-title":"Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: A 9-month follow-up to a 3-month randomized trial","volume":"113","author":"Solli","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2021.108656_bb0175","series-title":"Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017"},{"year":"2020","author":"Steiro","key":"10.1016\/j.jsat.2021.108656_bb0180"},{"issue":"12","key":"10.1016\/j.jsat.2021.108656_bb0185","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamapsychiatry.2017.3206","article-title":"Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: A randomized clinical noninferiority trial","volume":"74","author":"Tanum","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.jsat.2021.108656_bb0190","doi-asserted-by":"crossref","DOI":"10.1186\/s13722-019-0166-0","article-title":"Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail","volume":"14","author":"Velasquez","year":"2019","journal-title":"Addiction Science & Clinical Practice"},{"issue":"1","key":"10.1016\/j.jsat.2021.108656_bb0195","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1172\/JCI134708","article-title":"Medications for opioid use disorders: Clinical and pharmacological considerations","volume":"130","author":"Volkow","year":"2020","journal-title":"Journal of Clinical Investigation"},{"year":"2009","series-title":"Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence","key":"10.1016\/j.jsat.2021.108656_bb0200"},{"key":"10.1016\/j.jsat.2021.108656_bb0205","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.12.031","article-title":"Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis","volume":"160","author":"Yarborough","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.jsat.2021.108656_bb0210","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1046\/j.1360-0443.2003.00354.x","article-title":"Does retention matter? Treatment duration and improvement in drug use","volume":"98","author":"Zhang","year":"2003","journal-title":"Addiction"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221003822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221003822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:55:08Z","timestamp":1760039708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221003822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":42,"alternative-id":["S0740547221003822"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108656","relation":{},"ISSN":["0740-5472"],"issn-type":[{"type":"print","value":"0740-5472"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108656","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108656"}}